NASDAQ · AIRS

AirSculpt Technologies, Inc.

$4.61 -$0.06 (-1.28%) 1D Market open

Key Metrics

$325.22M
Market cap
P/E · TTM
$151.84M
Revenue · TTM
−$11.22M
Net income
EPS · TTM $-0.19
Dividend yield
Free cash flow $6.95M
Beta · 1Y 2.46
EBITDA · TTM −$4.73M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 1
    The stock moved +23.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 1
  • Mar 16
    The stock moved +51.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 16
  • Feb 27
    From its Jan 30 high, the share price fell 47%.

    Peak close $2.97 on Jan 30; trough close $1.58 on Feb 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -47%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$325.22M
Enterprise value$353.34M
Shares outstanding70.5M
52-wk range$1.51 – $12.00
Avg volume · 20D469.2K
Net cash −$28.13M
Book value / share$1.71
IndustryServices-Offices & Clinics Of Doctors Of Medicine
ExchangeNASDAQ
About AirSculpt Technologies, Inc.
IPO dateOct 29, 2021
Employees363

AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.14
P/FCF46.83
EV/EBITDA
EV/Sales2.33
Graham №

Profitability

Gross
Operating -11.4%
Net -7.4%
FCF 4.6%
ROE / ROIC -12.5% · -8.7%

Financial Health

Current ratio0.75
Quick ratio
Debt / equity0.45
Debt / EBITDA -9.48
Net cash −$28.13M
Working capital−$8.15M

Cash Flow · TTM

Operating CF $7.50M
Capex −$554.00K
Free cash flow $6.95M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

2.3
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings